Previous Page  3 / 5 Next Page
Information
Show Menu
Previous Page 3 / 5 Next Page
Page Background

Volume 2

Journal of Molecular Cancer

Cancer & Primary Healthcare 2019

May 20-21, 2019

Page 12

Cancer Research & Oncology

Primary Healthcare and Medicare Summit

May 20-21, 2019 | Rome, Italy

25

th

Global Meet on

World Congress on

&

Ondrej Slaby

Masaryk University, Czech Republic

J Mol Cancer, Volume 2

Translational potential of non-coding RNAs in oncology

For many years, central dogma of molecular biology has been that RNA functions mainly as an

informational intermediate between DNA sequence and its encoded protein. One of the great surprises

of modern biology was discovery that protein-coding genes represent less than 2% of total genome

sequence, and subsequently that almost 90% of human genome is actively transcribed. Thus, human

transcriptome was found to be more complex than collection of protein-coding gene transcripts and

their splice variants. Recent evidences have clearly shown that non-coding RNAs (ncRNAs) play major

biological roles in cellular development, physiology and pathologies. NcRNAs are grouped into two

major classes based on transcript size; small ncRNAs and long ncRNAs. Each of these classes can be

further divided, whereas novel subclasses are still being discovered and characterized. In last ten years,

class of small ncRNAs called microRNAs was studied most intensively with more than fifty thousand

hits at PubMed database. Huge amount of evidence has been accumulated to describe molecular

mechanisms of novel RNA species functioning, providing insight into their functional roles in cellular

biology and in human disease, especially in cancer. Knowledge regarding ncRNAs functioning in cancer

biology and their translational potential to serve as disease biomarkers and novel therapeutic targets in

cancer will be summarized and demonstrated on several examples based on our recent observations.

Biography

Ondrej Slaby is a Professor of Medical Biochemistry at the the 1st Faculty of Medicine at Charles University in Prague, Czech Republic. He

works as Research Group Leader at the Department of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk

University (Brno, Czech Republic) and as a Scientific Secretary at the Masaryk Memorial Cancer Institute in Brno. He has published exten-

sively in the field of non-coding RNAs and solid cancer with special focus on their translational potential in diagnostics and as the therapeutic

targets (h-index 31, Sum of the times cited without auto-citations > 3500. Since 2018, he is a chair of Czechoslovak Biological Society. In

2010 and 2012, he received Award of Czech Society for Oncology, in 2016 an Award of Czech Medical Society and 2014 and 2016 Award

for Medical Research of Czech Minister of Health, Novartis Discovery Award 2017.

on.slaby@gmail.com